Patrys has today announced that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a rebate of $1.285 million for the 2023/2024 financial year under the Federal Government’s R&D Tax Incentive scheme.
The Research & Development (R&D) Tax Incentive helps companies innovate and grow by providing a tax offset for eligible research and development. The majority of the development costs associated with Patrys’ dexoymab program benefit from this scheme.
Click to read the ASX release.
Patrys Receives R&D Tax Incentive Refund
